Andrology & STDs Department, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Adam International Hospital, Giza, Egypt.
Urologia. 2020 Nov;87(4):185-190. doi: 10.1177/0391560320913401. Epub 2020 Apr 23.
The aim of this prospective study was to determine whether there is a beneficial role of combining gonadotropin administration with testosterone downregulation in non-obstructive azoospermia patients prior to a second time microsurgical testicular sperm extraction after a negative one.
A total of 40 non-obstructive azoospermia men were recruited from a specialized IVF center from 2014 to 2016. Participants were divided equally into two groups: Group A was subjected to testosterone downregulation alone for 1 month and then combined with gonadotropin administration for 3 months prior to second time testicular sperm extraction; Group B (controls) underwent second time microsurgical testicular sperm extraction without prior hormonal therapy.
Mean baseline follicle-stimulating hormone levels of the controls and the cases were 26.9 ± 11.8 and 25.4 ± 8.7, respectively. One month after testosterone downregulation, follicle-stimulating hormone level of the cases was normalized and became 2.4 ± 1.2. There was no statistically significant difference between baseline follicle-stimulating hormone levels of the controls and cases (p = 0.946). Remarkably, two cases were positive after downregulation (10%) and no controls were positive at second testicular sperm extraction (0%). There was no statistically significant difference between sperm retrieval after the second microsurgical testicular sperm extraction in the controls and the cases (p = 0.072).
Patients who underwent first time testicular sperm extraction with unfavorable outcome due to different techniques may benefit from testosterone downregulation combined with neoadjuvant gonadotropin administration as it had shown positive sperms retrieval in 2 out of the 20 cases, especially those with hypergonadotropic azoospermia.
本前瞻性研究旨在确定在首次失败的睾丸精子提取术之后,对非梗阻性无精子症患者进行第二次显微睾丸精子提取术之前,联合使用促性腺激素给药和睾酮下调是否具有有益作用。
2014 年至 2016 年,从一家专门的体外受精中心招募了 40 名非梗阻性无精子症男性。参与者被平均分为两组:A 组仅接受睾酮下调治疗 1 个月,然后在第二次睾丸精子提取术之前联合使用促性腺激素给药治疗 3 个月;B 组(对照组)未进行激素治疗,直接进行第二次显微睾丸精子提取术。
对照组和病例组的基础卵泡刺激素水平分别为 26.9±11.8 和 25.4±8.7。睾酮下调 1 个月后,病例组的卵泡刺激素水平正常化,达到 2.4±1.2。对照组和病例组的基础卵泡刺激素水平无统计学差异(p=0.946)。值得注意的是,下调后有 2 例(10%)呈阳性,而对照组在第二次睾丸精子提取术时均为阴性(0%)。对照组和病例组在第二次显微睾丸精子提取术后的精子获取率无统计学差异(p=0.072)。
由于不同的技术,首次睾丸精子提取术结果不佳的患者可能受益于睾酮下调联合新辅助促性腺激素给药,因为它显示出在 20 例中有 2 例(10%)获得了阳性精子,特别是那些高促性腺激素无精子症患者。